Financial Performance - The company's operating revenue for Q3 2021 was ¥82,468,724.46, a decrease of 25.60% compared to the same period last year[3] - The net profit attributable to shareholders was -¥8,066,309.62, representing a decline of 139.16% year-on-year[3] - The net cash flow from operating activities for the year-to-date was ¥45,233,363.79, down 60.35% compared to the previous year[3] - Total operating revenue for the current period is CNY 247,947,794.28, a decrease from CNY 327,144,354.11 in the previous period[21] - The net profit for the current period is a loss of CNY 20,837,651.13, compared to a net profit of CNY 71,338,382.32 in the previous period[22] - The total comprehensive income for the current period is a loss of CNY 20,837,651.13, contrasting with a comprehensive income of CNY 71,338,382.32 in the previous period[23] - The basic and diluted earnings per share for the current period are both -CNY 0.14, compared to CNY 0.62 in the previous period[23] Assets and Liabilities - Total assets at the end of the reporting period reached ¥811,396,490.53, an increase of 23.26% from the end of the previous year[3] - The company's current assets reached CNY 258,756,671.57, significantly up from CNY 93,128,867.49 at the end of 2020, indicating a growth of about 177.5%[17] - The cash and cash equivalents increased to CNY 96,787,981.33 from CNY 33,539,499.25, marking a rise of approximately 188.5%[17] - Accounts receivable rose to CNY 3,177,045.85, compared to CNY 2,367,326.39 at the end of 2020, reflecting an increase of about 34.2%[17] - The total liabilities decreased to CNY 202,977,418.80 from CNY 257,613,680.09, a reduction of approximately 21.2%[19] - The company has no long-term borrowings as of the end of the reporting period, reflecting a 100% decrease in long-term debt[9] - The company reported a decrease in short-term borrowings to CNY 70,975,354.15 from CNY 88,058,208.33, a decline of approximately 19.5%[19] Equity and Shareholder Information - The company's equity attributable to shareholders increased by 51.86% to ¥608,419,071.73 compared to the previous year[4] - The company's equity attributable to shareholders increased to CNY 608,419,071.73 from CNY 400,653,822.86, representing a growth of about 52%[19] - The company issued 38.375 million shares in April 2021, raising net funds of ¥228,602,900, contributing to the increase in total assets and equity[10] Research and Development - Research and development expenses surged by 877.80% to ¥1,850,000.00 due to increased outsourcing for collaborative R&D[9] - Research and development expenses increased significantly to CNY 1,850,000.00 from CNY 189,200.00 in the previous period[22] Income and Costs - The gross profit margin and net profit were significantly impacted by a decline in product sales prices and an increase in raw material costs[9] - Total operating costs increased to CNY 283,869,098.02 from CNY 258,874,817.18, with operating costs specifically rising from CNY 233,855,538.57 to CNY 257,654,857.79[22] Other Income and Cash Flow - The company reported a significant increase in other income, which rose by 374.99% to ¥17,183,336.65, primarily due to increased government subsidies[9] - The cash flow from operating activities generated a net cash flow of CNY 45,233,363.79, down from CNY 114,095,071.40 in the previous period[25] - The net cash flow from financing activities was CNY 150,604,885.64, compared to a negative cash flow of CNY 78,221,562.30 in the previous period[26] - Cash and cash equivalents at the end of the period increased to CNY 196,787,981.33 from CNY 23,883,765.19 in the previous period[26] - The company raised CNY 233,160,500.00 from investment activities during the current period[26] Reporting and Compliance - The third quarter report of Fujian Wancheng Biotechnology Co., Ltd. has not been audited[29] - The board of directors has confirmed the unaudited status of the third quarter report[29] - The company has implemented new leasing standards starting from 2021, with retrospective adjustments to prior comparative data[29] - The report is part of the company's ongoing compliance with financial reporting standards[29] Future Outlook and Strategy - Future outlook and performance guidance are not mentioned in the document[29] - No new products or technologies are discussed in the document[29] - There are no details on market expansion or mergers and acquisitions provided[29] - The document does not outline any new strategies[29] - There are no specific financial performance metrics or user data provided in the document[29] - The company has not disclosed any revenue figures or growth percentages[29]
万辰集团(300972) - 2021 Q3 - 季度财报